Navigation Links
NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Date:3/18/2008

SAN MATEO, Calif., March 18 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will report results for its fourth quarter and year-end 2007 on Wednesday, March 26, 2008, after the market closes.

A conference call to review the results will begin at 5:00 p.m. ET (2:00 p.m. PT) on March 26, 2008 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.

To participate in the conference call, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). In addition, a dial-up replay of the conference call will be available beginning March 26, 2008 at 8:00 p.m. ET (5:00 p.m. PT) and ending on April 5, 2008. The replay telephone number is 1- 877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 275941.

A live web cast of the call will also be available from the Investor Relations section on the corporate web site at http://www.neurogesx.com. A web cast replay can be accessed on the corporate web site beginning March 26, 2008 at approximately 6:00 p.m. ET. The replay will remain available until April 26, 2008.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements concerning future presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc. The Ruth Group

Stephen Ghiglieri Investors / Media

(650) 358-3300 Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
2. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
3. NeurogesX Closes $25 Million Private Placement
4. NeurogesX, Inc. Announces $25 Million Private Placement
5. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
6. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. NeurogesX Expands Senior Management Team
8. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
9. NeurogesX Appoints New Director to the Board
10. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
11. Vion Reports 2007 Fourth Quarter and Year-End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... and VANCOUVER, British Columbia , Feb. 21, ... today announced that apatorsen results from two randomized Phase 2 ... Oncology (ASCO) 2017 Genitourinary Cancers Symposium, held February 16 th ... Clinical data from trials in bladder and prostate cancers demonstrated ... combination with standard-of-care treatments. ...
(Date:2/21/2017)...   Logicalis Healthcare Solutions , the healthcare-focused practice ... services provider ( www.us.logicalis.com ), today announced a new ... new service will help hospital CIOs make the best ... nurses and other clinicians immediate access to a pool ... allow hospital IT staff to focus on broader issues ...
(Date:2/21/2017)... 21, 2017   Invitae Corporation (NYSE: NVTA), ... announced that members of the company,s management team will ... Care Conference on Monday, March 6, 2017 at approximately ... Boston, Massachusetts . The ... by visiting the investors section of the company,s website ...
(Date:2/20/2017)... ... February 20, 2017 , ... Global relationship marketing ... approved for full, active membership in the Canadian Direct Sellers Association (DSA) effective ... Executive Officer Jeff Olson in 2011. Today Nerium International, with its ...
Breaking Biology Technology:
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/3/2017)... Biomedical Research Institute announced that its Board of Trustees has ... Institute,s new President and CEO. Dr. Schlesinger will take the ... currently the Chair of the Department of Microbial Infection and ... at Ohio State University. "We are delighted to ... Texas Biomed," said Dr. James O. Rubin , Board ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):